1. Home
  2. GENK vs IGC Comparison

GENK vs IGC Comparison

Compare GENK & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GENK
  • IGC
  • Stock Information
  • Founded
  • GENK 2011
  • IGC 2005
  • Country
  • GENK United States
  • IGC United States
  • Employees
  • GENK N/A
  • IGC N/A
  • Industry
  • GENK Restaurants
  • IGC Biotechnology: Pharmaceutical Preparations
  • Sector
  • GENK Consumer Discretionary
  • IGC Health Care
  • Exchange
  • GENK Nasdaq
  • IGC Nasdaq
  • Market Cap
  • GENK 36.5M
  • IGC 29.4M
  • IPO Year
  • GENK 2023
  • IGC N/A
  • Fundamental
  • Price
  • GENK $5.50
  • IGC $0.31
  • Analyst Decision
  • GENK Strong Buy
  • IGC Strong Buy
  • Analyst Count
  • GENK 3
  • IGC 2
  • Target Price
  • GENK $13.17
  • IGC $3.75
  • AVG Volume (30 Days)
  • GENK 60.1K
  • IGC 390.0K
  • Earning Date
  • GENK 03-05-2025
  • IGC 02-25-2025
  • Dividend Yield
  • GENK N/A
  • IGC N/A
  • EPS Growth
  • GENK 483.78
  • IGC N/A
  • EPS
  • GENK 0.17
  • IGC N/A
  • Revenue
  • GENK $198,834,000.00
  • IGC $1,236,000.00
  • Revenue This Year
  • GENK $14.66
  • IGC N/A
  • Revenue Next Year
  • GENK $21.47
  • IGC $13.38
  • P/E Ratio
  • GENK $31.92
  • IGC N/A
  • Revenue Growth
  • GENK 12.50
  • IGC N/A
  • 52 Week Low
  • GENK $5.46
  • IGC $0.27
  • 52 Week High
  • GENK $14.46
  • IGC $0.91
  • Technical
  • Relative Strength Index (RSI)
  • GENK 19.19
  • IGC 42.69
  • Support Level
  • GENK $5.50
  • IGC $0.29
  • Resistance Level
  • GENK $6.42
  • IGC $0.33
  • Average True Range (ATR)
  • GENK 0.32
  • IGC 0.01
  • MACD
  • GENK -0.04
  • IGC 0.00
  • Stochastic Oscillator
  • GENK 2.88
  • IGC 43.20

About GENK GEN Restaurant Group Inc.

GEN Restaurant Group Inc is an Asian casual dining restaurant in the United States. It offers an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables.

About IGC IGC Pharma Inc.

IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

Share on Social Networks: